Intellia Therapeutics, Inc.
NTLA
$7.25
-$1.19-14.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -7.86% | -12.94% | -12.21% | -12.79% | -1.48% |
| Total Depreciation and Amortization | 14.58% | 19.25% | 20.31% | 19.95% | 18.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.32% | 7.91% | -1.30% | -12.81% | -30.24% |
| Change in Net Operating Assets | 122.65% | 118.77% | 82.47% | 38.14% | 2.64% |
| Cash from Operations | 11.47% | 8.74% | -1.42% | -11.74% | -18.24% |
| Capital Expenditure | 58.68% | 61.43% | 42.45% | 20.69% | -3.15% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 856.51% | 128.84% | 194.61% | 1,610.60% | -109.99% |
| Cash from Investing | 500.57% | 118.56% | 176.92% | 1,128.50% | -119.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 42.53% | -45.26% | -57.56% | -65.03% | -77.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 42.53% | -45.26% | -57.56% | -65.03% | -77.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.27% | -249.97% | -244.86% | -172.77% | -171.98% |